NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study ...
NiKang Therapeutics® Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback